Viyash Scientific Limited (VIYASH) Q2 FY27 Financial Results: PAT ₹793 Cr & Revenue ₹9,464 Cr

11 August 2026 · NSE 🔴 High Importance ✨ Positive

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

Metric	Value
Revenue	₹9,464 Cr
Net Profit (PAT)	₹793 Cr

📢 Key Event

Viyash reports Q1 FY27 revenue of ₹9,464 million, up 19.5% YoY

🔄 What Changed

Revenue grew 19.5% YoY to ₹9,464 million; EBITDA rose 59.2% YoY to ₹2,047 million; PAT surged 114.9% YoY to ₹793 million; EBITDA margin improved to 21.6% from 16.2%

🔮 What's Next

Management highlighted focus on disciplined execution, operational efficiency, and strategic investments for sustainable growth

💡 Investor Takeaway

Strong top-line and bottom-line growth signals successful integration and margin expansion, supporting long-term growth outlook

Viyash Scientific Limited reported Q1 FY27 consolidated revenues of ₹9,464 million, up 19.5% YoY, with EBITDA at ₹2,047 million (+59.2% YoY) and PAT at ₹793 million (+114.9% YoY). EBITDA margin expanded to 21.6% from 16.2% a year earlier. Net debt/EBITDA stood at 0.1x. The company highlighted integration progress and European market entry via its Italy acquisition.

📄 View Original Announcement (PDF)

📊 Stock Analysis — VIYASH ✨ Ask AI About This

About Viyash Scientific Limited (VIYASH)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹10,303.71 CrP/E: 38.6ROE: 7.5%ROCE: 14.6%

View full VIYASH stock details →

📡 Get AI alerts when VIYASH files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track VIYASH — Free

💡 Ask AI about this filing

"How does the Italy acquisition impact European revenue contribution?""What is the target EBITDA margin for FY27?""When will net debt/EBITDA ratio improve beyond 0.1x?"

Ask AI Free →

📊 More VIYASH filings

🔴 Corporate Action — 1 October 2026Viyash Scientific completed its acquisition of 100% of BioForLife Italia S.r.l. on October 1, 2026, ...
Announcement — 28 September 2026Viyash Scientific Limited announced that its trading window will close on October 1, 2026, and remai...
🔴 Corporate Action — 18 September 2026Viyash Scientific announced the allotment of 11,07,309 equity shares under its ESOP 2020 and ESOP 20...
🔴 Announcement — 8 September 2026Viyash Scientific announced that Italian regulatory approval for its proposed acquisition of BioForL...
🔴 Corporate Action — 4 September 2026Viyash Scientific announced the allotment of 612,773 equity shares under its 2020 and 2026 employee ...

See all VIYASH filings →

🔥 Also filed on 11 August 2026

ULTRACEMCOUltraTech Cement LimitedAnnouncement SUDEEPPHRMSudeep Pharma LimitedFinancial Results SUTLEJTEXSutlej Textiles and Industries LimitedFinancial Results RBZJEWELRBZ Jewellers LimitedFinancial Results TATVATatva Chintan Pharma Chem LimitedCorporate Action AETHERAether Industries LimitedCorporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIYASH files new disclosures

Track VIYASH filings, board meetings, and corporate actions. Free email alerts at 5 PM.